WO1993000330A3 - Azanorbornane derivatives - Google Patents

Azanorbornane derivatives Download PDF

Info

Publication number
WO1993000330A3
WO1993000330A3 PCT/US1992/004697 US9204697W WO9300330A3 WO 1993000330 A3 WO1993000330 A3 WO 1993000330A3 US 9204697 W US9204697 W US 9204697W WO 9300330 A3 WO9300330 A3 WO 9300330A3
Authority
WO
WIPO (PCT)
Prior art keywords
azanorbornane derivatives
formula
azanorbornane
derivatives
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1992/004697
Other languages
French (fr)
Other versions
WO1993000330A2 (en
Inventor
Brian Thomas O'neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to DE69217945T priority Critical patent/DE69217945T2/en
Priority to EP92913342A priority patent/EP0591333B1/en
Priority to FI935726A priority patent/FI935726L/en
Priority to JP5501492A priority patent/JPH0788356B2/en
Priority to KR1019930703962A priority patent/KR940701384A/en
Priority to US08/167,851 priority patent/US5604252A/en
Publication of WO1993000330A2 publication Critical patent/WO1993000330A2/en
Publication of WO1993000330A3 publication Critical patent/WO1993000330A3/en
Priority to NO934727A priority patent/NO934727L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Ink Jet (AREA)
  • Fertilizers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to novel azanorbornane derivatives having formula (I), wherein R1 through R12 are as defined in the description, and to novel intermediates used in their synthesis. The compounds having formula (I) are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
PCT/US1992/004697 1991-06-21 1992-06-11 Azanorbornane derivatives Ceased WO1993000330A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE69217945T DE69217945T2 (en) 1991-06-21 1992-06-11 AZANORBORN OTHER DERIVATIVES
EP92913342A EP0591333B1 (en) 1991-06-21 1992-06-11 Azanorbornane derivatives
FI935726A FI935726L (en) 1991-06-21 1992-06-11 AZANORBORNANDERIVAT
JP5501492A JPH0788356B2 (en) 1991-06-21 1992-06-11 Azanorbornane derivative
KR1019930703962A KR940701384A (en) 1991-06-21 1992-06-11 Azanorbornane derivatives
US08/167,851 US5604252A (en) 1991-06-21 1992-06-11 Azanorbornane derivatives
NO934727A NO934727L (en) 1991-06-21 1993-12-20 Azanorbornan derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71988491A 1991-06-21 1991-06-21
US719,884 1991-06-21

Publications (2)

Publication Number Publication Date
WO1993000330A2 WO1993000330A2 (en) 1993-01-07
WO1993000330A3 true WO1993000330A3 (en) 1993-03-04

Family

ID=24891766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/004697 Ceased WO1993000330A2 (en) 1991-06-21 1992-06-11 Azanorbornane derivatives

Country Status (18)

Country Link
US (1) US5604252A (en)
EP (1) EP0591333B1 (en)
KR (1) KR940701384A (en)
AT (1) ATE149497T1 (en)
AU (1) AU2188992A (en)
CA (1) CA2111335A1 (en)
DE (1) DE69217945T2 (en)
DK (1) DK0591333T3 (en)
FI (1) FI935726L (en)
HU (1) HUT68957A (en)
IE (1) IE921987A1 (en)
IL (1) IL102208A0 (en)
MX (1) MX9203053A (en)
NO (1) NO934727L (en)
PT (1) PT100607A (en)
TW (1) TW202432B (en)
WO (1) WO1993000330A2 (en)
ZA (1) ZA924527B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7265116B2 (en) 1999-11-03 2007-09-04 Arm Technology, Inc. Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof
US7309789B2 (en) 2000-07-11 2007-12-18 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US9173879B2 (en) 2009-05-12 2015-11-03 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9403776B2 (en) 2005-07-15 2016-08-02 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
DE69231395T3 (en) 1991-09-20 2005-07-21 Glaxo Group Ltd., Greenford New medical indication for tachykinin antagonists
EP0641328B1 (en) * 1992-05-18 2001-11-21 Pfizer Inc. Bridged aza-bicyclic derivatives as substance p antagonists
AU4396193A (en) * 1992-08-04 1994-03-03 Pfizer Inc. 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
ATE208376T1 (en) * 1992-08-19 2001-11-15 Pfizer NON-AROMATIC HETEROCYCLES CONTAINING SUBSTITUTED BENZYLAMINE NITROGEN
CA2150123C (en) * 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
FR2700472B1 (en) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Synergizing association having an antagonistic effect on the NK1 and NK2 receptors.
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment and prevention of solar erythema.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists for the inhibition of angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
CA2198084C (en) 1994-08-25 2000-03-28 Timothy P. Burkholder Novel substituted piperidines useful for the treatment of allergic diseases
FR2728165A1 (en) 1994-12-19 1996-06-21 Oreal USE OF AN ANTAGONIST OF SUBSTANCE P FOR THE TREATMENT OF SKIN REDNESS OF NEUROGENIC ORIGIN
FR2728169A1 (en) 1994-12-19 1996-06-21 Oreal USE OF A SUBSTANCE P ANTAGONIST FOR THE TREATMENT OF PRURITUS AND EYE OR PALPEBRAL DYSESTHESIA
FR2728166A1 (en) 1994-12-19 1996-06-21 Oreal TOPICAL COMPOSITION CONTAINING AN ANTAGONIST OF SUBSTANCE P
JP3950170B2 (en) * 1995-04-13 2007-07-25 アベンティス・ファーマスーティカルズ・インコーポレイテッド Novel substituted piperazine derivatives with tachykinin receptor antagonist activity
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
FR2741262B1 (en) 1995-11-20 1999-03-05 Oreal USE OF A TNF-ALPHA ANTAGONIST FOR THE TREATMENT OF CUTANEOUS REDNESS OF NEUROGENIC ORIGIN
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
JP2001172178A (en) * 1999-10-25 2001-06-26 Pfizer Prod Inc Nk-1 receptor antagonist and eletriptan for treating megrim
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
US7119207B2 (en) * 2000-04-10 2006-10-10 Pfizer Inc Benzoamide piperidine containing compounds and related compounds
HUP0300413A2 (en) * 2000-04-10 2003-06-28 Pfizer Products Inc. Benzoamide piperidine containing and related compounds, process for their preparation and pharmaceutical compositions containing them
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
CN101094846A (en) * 2004-10-18 2007-12-26 伊莱利利公司 1-(Hetero)aryl-3-amino-pyrrolidine derivatives useful as MGLUR3 receptor antagonists
ES2382814T3 (en) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Cis-4 - [(4-chlorophenyl) sulfonyl] -4- (2,5-difluorophenyl) cyclohexanopropanoic acid for cancer treatment
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (en) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Amide substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors
JP5319518B2 (en) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 Indoledione derivative
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AU2009222122A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
UA105182C2 (en) 2008-07-03 2014-04-25 Ньюрексон, Інк. Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
PE20121172A1 (en) 2009-10-14 2012-09-05 Merck Sharp & Dohme PIPERIDINS SUBSTITUTED WITH ACTIVITY IN HDM2
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (en) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Novel compounds that are erk inhibitors
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
RS56680B1 (en) 2012-11-28 2018-03-30 Merck Sharp & Dohme Compositions and methods for treating cancer
KR102196882B1 (en) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020254552A2 (en) 2019-06-19 2020-12-24 Grünenthal GmbH Substituted pyrrolidine amides v

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362941A2 (en) * 1988-10-07 1990-04-11 Merck Sharp & Dohme Ltd. 4-Methyl and 4-ethyl substituted pyrrolidin-2-ones
WO1990005729A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine therapeutic agents
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
WO1992001688A1 (en) * 1990-07-23 1992-02-06 Pfizer Inc. Quinuclidine derivatives
WO1992006079A1 (en) * 1990-09-28 1992-04-16 Pfizer Inc. Fused ring analogs of nitrogen containing nonaromatic heterocycles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH072740B2 (en) * 1990-06-01 1995-01-18 フアイザー・インコーポレイテツド 3-amino-2-arylquinuclidine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362941A2 (en) * 1988-10-07 1990-04-11 Merck Sharp & Dohme Ltd. 4-Methyl and 4-ethyl substituted pyrrolidin-2-ones
WO1990005729A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine therapeutic agents
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
WO1992001688A1 (en) * 1990-07-23 1992-02-06 Pfizer Inc. Quinuclidine derivatives
WO1992006079A1 (en) * 1990-09-28 1992-04-16 Pfizer Inc. Fused ring analogs of nitrogen containing nonaromatic heterocycles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACTA CHEM. SCAND. SER. B vol. B35, no. 7, 1981, pages 3557 - 70; P. THORBEK ET AL.: 'Synthese and proton NMR spectroscopic investigations of some pyrrolidinecarboxylic acids designed as potential glial GABA uptake inhibitors' compounds of formulae 17 to 20 *
J. MED. CHEM. vol. 17, no. 5, 1974, pages 497 - 501; E.J. WARAWA ET AL.: 'Quinuclidine Chemistry. 2. Synthesis and Antiinflammatory Properties of 2-Substituted Benzhydryl-3-quinuclidinols' compounds 2, 3, 6 and 7 compounds of general formulae III & IV *
J. MED. CHEM. vol. 18, no. 1, 1975, pages 71 - 74; E.J. WARAWA ET AL.: 'Quinuclidine Chemistry. 3. 1beta-cis-2-(4'-cis-2-(4'-Chlorobenzhydryl)-3-qu inuclidinol, a New Central Nervous System Stimulant. Importance of the Benzhydryl Configuration' *
J. MED. CHEM. vol. 18, no. 6, 1975, pages 587 - 593; E.J. WARAWA ET AL.: 'Quinuclidine Chemistry. 4. Diuretic properties of cis-3-amino-2-benzhydrylquinuclidine' compounds of general formula III *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7265116B2 (en) 1999-11-03 2007-09-04 Arm Technology, Inc. Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof
US7612090B2 (en) 1999-11-03 2009-11-03 Albany Molecular Research, Inc. Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof
US7309789B2 (en) 2000-07-11 2007-12-18 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US7419985B2 (en) 2000-07-11 2008-09-02 Amr Technology, Inc. 4-Phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9499531B2 (en) 2004-07-15 2016-11-22 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9403776B2 (en) 2005-07-15 2016-08-02 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US9498476B2 (en) 2008-06-04 2016-11-22 Albany Molecular Research, Inc. Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US9173879B2 (en) 2009-05-12 2015-11-03 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof

Also Published As

Publication number Publication date
FI935726A0 (en) 1993-12-20
ZA924527B (en) 1993-12-20
IL102208A0 (en) 1993-01-14
KR940701384A (en) 1994-05-28
AU2188992A (en) 1993-01-25
DE69217945T2 (en) 1997-06-12
HUT68957A (en) 1995-08-28
PT100607A (en) 1993-08-31
FI935726A7 (en) 1993-12-20
IE921987A1 (en) 1992-12-30
TW202432B (en) 1993-03-21
HU9303666D0 (en) 1994-04-28
FI935726L (en) 1993-12-20
NO934727D0 (en) 1993-12-20
US5604252A (en) 1997-02-18
NO934727L (en) 1993-12-20
WO1993000330A2 (en) 1993-01-07
ATE149497T1 (en) 1997-03-15
DK0591333T3 (en) 1997-05-20
EP0591333B1 (en) 1997-03-05
EP0591333A1 (en) 1994-04-13
DE69217945D1 (en) 1997-04-10
CA2111335A1 (en) 1993-01-07
MX9203053A (en) 1992-12-01

Similar Documents

Publication Publication Date Title
WO1993000330A3 (en) Azanorbornane derivatives
CA2134964A1 (en) Bridged Aza-Bicyclic Derivatives as Substance P Antagonists
CA2157117A1 (en) Spirocyclic Piperidine Derivatives
CA2141048A1 (en) Substituted benzylamino nitrogen containing non-aromatic heterocycles
CA2150123A1 (en) Aminomethylene substituted non-aromatic heterocycles
CA2109613A1 (en) Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
BG104138A (en) 2-aminopyridines containing substituents with condensed rings as nos inhibitors
ZA917744B (en) Fused ring analogs of nitrogen containing nonaromatic heterocycles.
CA2111461A1 (en) 3-Aminopiperidine Derivatives and Related Nitrogen Containing Heterocycles
HU9601790D0 (en) Diazabicyclic neurokinin antagonists
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
FI931332A0 (en) Novel alkylenediammonium diclavulanate derivatives, process for their preparation as well as their use for the purification of calvulanic acid
UA49884C2 (en) a-hydro-carboxylic acid derivatives and their use as medicaments
PL336640A1 (en) Substituted 3,3-diamino-2- propenonitriles, their production and application
MXPA04006085A (en) Isochroman compounds for treatment of cns disorders.
AU2910800A (en) Novel substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines
CA2171972A1 (en) Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI HU JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI HU JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992913342

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2111335

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 08167851

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 935726

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1992913342

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992913342

Country of ref document: EP